5mt8: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Structure of E.coli GlpG in complex with peptide derived inhibitor Ac-RVRHA-cmk== | ==Structure of E.coli GlpG in complex with peptide derived inhibitor Ac-RVRHA-cmk== | ||
<StructureSection load='5mt8' size='340' side='right' caption='[[5mt8]], [[Resolution|resolution]] 1.95Å' scene=''> | <StructureSection load='5mt8' size='340' side='right'caption='[[5mt8]], [[Resolution|resolution]] 1.95Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5mt8]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MT8 OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[5mt8]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Escherichia_coli_K-12 Escherichia coli K-12] and [https://en.wikipedia.org/wiki/Providencia_stuartii Providencia stuartii]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MT8 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5MT8 FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.95Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=0QE:CHLOROMETHANE'>0QE</scene>, <scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene>, <scene name='pdbligand=BNG:B-NONYLGLUCOSIDE'>BNG</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5mt8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5mt8 OCA], [https://pdbe.org/5mt8 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5mt8 RCSB], [https://www.ebi.ac.uk/pdbsum/5mt8 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5mt8 ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/GLPG_ECOLI GLPG_ECOLI] Rhomboid-type serine protease that catalyzes intramembrane proteolysis.<ref>PMID:17099694</ref> <ref>PMID:16216077</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 20: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 5mt8" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5mt8" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Rhomboid protease|Rhomboid protease]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Escherichia coli K-12]] | ||
[[Category: Large Structures]] | |||
[[Category: | [[Category: Providencia stuartii]] | ||
[[Category: | [[Category: Vinothkumar KR]] | ||
[[Category: | |||
Latest revision as of 20:48, 8 November 2023
Structure of E.coli GlpG in complex with peptide derived inhibitor Ac-RVRHA-cmkStructure of E.coli GlpG in complex with peptide derived inhibitor Ac-RVRHA-cmk
Structural highlights
FunctionGLPG_ECOLI Rhomboid-type serine protease that catalyzes intramembrane proteolysis.[1] [2] Publication Abstract from PubMedRhomboid-family intramembrane proteases regulate important biological processes and have been associated with malaria, cancer, and Parkinson's disease. However, due to the lack of potent, selective, and pharmacologically compliant inhibitors, the wide therapeutic potential of rhomboids is currently untapped. Here, we bridge this gap by discovering that peptidyl alpha-ketoamides substituted at the ketoamide nitrogen by hydrophobic groups are potent rhomboid inhibitors active in the nanomolar range, surpassing the currently used rhomboid inhibitors by up to three orders of magnitude. Such peptidyl ketoamides show selectivity for rhomboids, leaving most human serine hydrolases unaffected. Crystal structures show that these compounds bind the active site of rhomboid covalently and in a substrate-like manner, and kinetic analysis reveals their reversible, slow-binding, non-competitive mechanism. Since ketoamides are clinically used pharmacophores, our findings uncover a straightforward modular way for the design of specific inhibitors of rhomboid proteases, which can be widely applicable in cell biology and drug discovery. General and Modular Strategy for Designing Potent, Selective, and Pharmacologically Compliant Inhibitors of Rhomboid Proteases.,Ticha A, Stanchev S, Vinothkumar KR, Mikles DC, Pachl P, Began J, Skerle J, Svehlova K, Nguyen MTN, Verhelst SHL, Johnson DC, Bachovchin DA, Lepsik M, Majer P, Strisovsky K Cell Chem Biol. 2017 Oct 12. pii: S2451-9456(17)30351-3. doi:, 10.1016/j.chembiol.2017.09.007. PMID:29107700[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||